Open AccessP1446: PHASE I STUDY DATA UPDATE OF PHE885, A FULLY HUMAN BCMA‐DIRECTED CAR‐T CELL THERAPY MANUFACTURED USING THE T‐CHARGETM PLATFORM FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM)
Author(s) -
Sperling A. S.,
Nikiforow S.,
Derman B.,
Nadeem O.,
Mo C.,
Laubach J.,
Anderson K.,
Alonso A.,
Im S.Y.,
Ikwgawa S.,
Prabhala R.,
Hernandez Rodriduez D.,
Daley H.,
Shaw K. L.,
Arihara Y.,
Ansari S.,
Quinn D. S.,
Pearson D.,
Hack A.,
Treanor L.,
Bu D.,
Mataraza J.,
Rispoli L.,
Credi M.,
Ritz J.,
Jakubowiak A.,
De Vita S.,
Munshi N.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000848640.53562.8f
Subject(s) - medicine , fludarabine , chimeric antigen receptor , adverse effect , t cell , population , cytokine release syndrome , cyclophosphamide , phases of clinical research , pharmacology , clinical trial , oncology , immunology , chemotherapy , immune system , environmental health